Elevated antibody titers in Abdala vaccinees evaluated by Elecsys® anti-SARS-CoV-2 S highly correlate with UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral neutralization assaysGilda Lemos, Gerardo Guillén, Yahima Chacón-Quintero et al.|medRxiv|2021Cited by 8
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical TrialGilda Lemos, Gerardo Guillén, Yinet Barrese-Pérez et al.|Vaccines|2024Cited by 5
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical TrialGilda Lemos, Gerardo Guillén, Yinet Barrese-Pérez et al.|Preprints.org|2024Cited by 2
Validation and clinical performance of a non-commercial ELISA for SARS-CoV-2 anti-RBD IgA antibodiesSheila Chávez-Valdés, Gilda Lemos, Ana K Marichal-Rodríguez et al.|Analytical Biochemistry|2025Cited by 1